JMB-2502 / Shanghai Jeyou Pharmaceutical - LARVOL DELTA

JMB-2502, a Novel and Potent Anti-BAFF (B-Cell Activating Factor)/APRIL (A Proliferation-Inducing Ligand) Bispecific Antibody with an Extended Half-Life for the Treatment of SLE and Other B-Cell-Related Autoimmune Diseases (ACR Convergence 2026) - "Current dual inhibitors (e.g., povetacicept) show clinical activity but are constrained by fusion protein architectures resulting in short half-lives. JMB-2502 is a novel bispecific antibody that neutralizes both BAFF and APRIL with ultra-high affinity, superior potency, and significantly enhanced PK/PD properties. These differentiated attributes support a potential extended dosing interval beyond 8 weeks, offering a distinct clinical advantage over current fusion proteins and providing a strong rationale for the clinical development of JMB-2502 in B-cell-mediated autoimmune diseases. Figure 1."

Bispecific • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Nephrology • Renal Disease